12:00 AM
 | 
Jul 04, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afluria regulatory update

CSL received a warning letter from FDA relating to deviations in cGMP practices in the manufacture of Afluria seasonal influenza vaccine and monovalent influenza bulks observed during a March inspection of the company's Parkville, Australia, site. The letter notes...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >